idea-008 · narrative
A synthesis across this candidate's claims, dossier and decks — every statement here traces to something that already exists elsewhere in the knowledge base. A narrative never invents a fact, upgrades a tag, or recommends anything.
How to read this. This is a synthesis, not a new source of truth: every claim it cites carries the tag the candidate file gives it right now, copied not paraphrased, and every line quoted from a deck is quoted verbatim. See docs/narrative-spec.md.
This is a single-use applicator that delivers bipolar radiofrequency energy through a disposable anoscope to coagulate and devascularise grade II and grade III internal hemorrhoids in the office, without sedation, priced to fit inside what CPT 46930 already pays. The regulatory shape is the best-evidenced part of the file: Class II, 510(k), and a modality — bipolar RF for internal hemorrhoids — with a four-clearance US history under the frontmatter's own lead route, product code GEI, 21 CFR 878.4400 [claim 40: verified]. What that history does not cover is the candidate's own stated premise: every located bipolar/RF predicate stops at grade II, and this candidate claims grade II and III [claim 42: verified]. Nothing about money, competition, or the device's own differentiator — impedance dosimetry — has ever been verified: reimbursement, TAM, and freedom-to-operate are all blank, and the file's sixteen verified claims are, without exception, database facts about what somebody else was permitted to sell. Since the last narrative, a business case appended eight further assumptions to the file — placement economics, channel cost, and a possible licensing route among them — and every one of them is unverified: not yet even attempted by a Verifier, let alone confirmed.
Grade II-III internal hemorrhoids are the band between conservative management, which has already failed, and full surgical hemorrhoidectomy, which is not yet required — the band where office rubber band ligation, infrared coagulation, and sclerotherapy compete against each other, all cheap and already owned by the proceduralist [dossier: internal-hemorrhoids-office-based-treatment]. The clinical gap this candidate is built around is no longer just asserted. A randomized, multicentre noninferiority trial found rubber band ligation was not noninferior to hemorrhoidectomy on 12-month quality-adjusted life years at grade III, with 47.5% recurrence against 6.1% for surgery [claim 59: unconfirmed]; a separate single-centre cohort found recurrence roughly doubles from grade I-II to grade III within office ligation itself, 32.8% against 14.6% [claim 60: unconfirmed]. The alternative that works carries the cost this device exists to avoid — across 79 randomized trials (n=9,232), closed hemorrhoidectomy had the lowest recurrence of 14 compared treatments but the surgical options carried the highest rates of postprocedural bleeding, urinary retention, and bowel incontinence [claim 61: unconfirmed]. None of these three findings is verified — Stage 3 rules withhold that tag pending Stage 7 expert appraisal — but each is a literature-detail hit whose numbers matched the retrieved abstract exactly.
The mechanism the candidate proposes to close that gap is impedance-based dosimetry with automatic cutoff, meant to devascularise the pedicle while sparing the sphincter complex and rectal wall [claim 12: unconfirmed], on hardware sized deliberately around a payment number: the candidate's own economic claim is that the kit must cost the practice materially less than the non-facility payment for 46930, or the office will not adopt it [claim 6: unconfirmed].
The regulatory picture is the one place this file has moved a long way. 21 CFR 878.4400 is confirmed as "Electrosurgical cutting and coagulation device and accessories," Class II [claim 16: verified], and its product code GEI, panel SU, is established [claim 17: verified]; the frontmatter's alternative "Part 876" route resolves to real named regulations rather than an unidentified guess [claim 18: verified]. Two Verifier propositions that had worked against the candidate were subsequently refuted: the reading that the panel question had moved toward Part 876 [claim 19: refuted], and the premise that no predicate had been identified at all, which would have implied a possible De Novo route [claim 46: refuted]. What replaced them is a four-clearance US history for a bipolar RF applicator indicated for internal hemorrhoids sitting on the frontmatter's own lead route [claim 40: verified], with a predicate carrying a checked Indications for Use [claim 20: verified]. The limit on all of that is exact and load-bearing: every one of those bipolar/RF clearances — K121085, K140422, K200146 — is capped at grade II [claim 52: verified]; the only located predicate spanning grade III is a 2003 device in a different product code and panel [claim 53: verified]. Whether FDA will accept a 510(k) that extends a grade-II predicate history to grade III is an open substantial-equivalence question this file records but cannot answer [claim 51: unconfirmed].
Reimbursement never got past the starting line. The CPT descriptor claim is unverifiable by design — CPT is AMA-licensed and no connector can ever resolve it [claim 1: unconfirmed] — and the payment and coverage checks both hit a missing local cache rather than a finding [claim 5: unconfirmed]. Two administrative facts arrived by a different route, through the research lane rather than a connector, and both cut in the candidate's favor: under the CY2026 Physician Fee Schedule, 46930/46945/46946 each carry a 90-day global surgical period, meaning a recurrence inside three months is not separately billable and lands on the physician's own P&L [claim 57: unconfirmed], and the non-facility total RVU for 46930 (7.42) is higher than the facility total (4.72) — the office is the higher-paying setting, not the lower one [claim 58: unconfirmed]. Both are unconfirmed because a dataset retrieval is not a Verifier pass, not because either number is in doubt.
Competitive intensity moved the other way. The field the second and third Verifier passes surfaced is busier than the file first recorded: a Covidien/Medtronic-owned bipolar RF hemorrhoid line with clearances through 2020 [claim 40: verified], and a single-use anoscope already carrying a hemorrhoid indication through grade III, cleared 2025-10-09 [claim 44: verified], [claim 55: verified] — occupying the exact delivery-vehicle position this candidate's own kit depends on. One presumed entrant was verified back out of the field: F Care Systems' complete US portfolio is three clearances, all venous or aesthetic, none anorectal, and its most recent clearance (Veineo, K253918) is an endovascular vein-reflux device, not a hemorrhoid predicate on the record [claim 37: verified]. Whether Veineo is the "RAFAELO" system named in international literature is asserted in neither direction [claim 38: verified], [claim 36: unconfirmed], and RAFAELO's own EU regulatory status is a question this repo's connectors cannot reach at all — no jurisdiction-EU source exists for it [claim 39: unconfirmed]. Freedom to operate has never been examined: no patent number is named and the patent connector has no API key configured, so zero patents have been searched in either direction [claim 11: unconfirmed], [claim 34: unconfirmed].
Since the previous build of this narrative, a business case was added to the file and appended eight further claims, dated 2026-09-03 — not deck-surfaced assumptions run through a Verifier pass this time, but business-case assumptions recorded as unverified because no pass has touched them at all yet: whether a contract-manufacturing quote for the applicator lands under the price ceiling the economic claim implies [claim 65: unverified]; whether the RF console can be placed into a practice at little or no upfront capital cost, recovered through a razor-and-blade consumable margin [claim 66: unverified]; whether a purchasing practice's own procedure volume clears a normal capital-equipment payback window [claim 67: unverified]; whether adoption by year 3-5 reaches the pace needed to hit the file's own 15-25% addressable- share figure [claim 68: unverified]; whether the lag between clearance and the first paid consumable order is short enough to finance inside a normal launch runway [claim 69: unverified]; whether the cost of building a sales and distribution channel into these practices is affordable within a launch budget [claim 70: unverified]; whether the impedance-dosimetry control module could instead be licensed or OEM'd into an already-cleared host device without triggering a new full 510(k) [claim 71: unverified]; and whether a US comparative study large enough to demonstrate grade-III superiority over rubber band ligation is affordable and runnable in a useful calendar [claim 72: unverified]. None of these eight moves a tag or a score — they widen the inventory of what the file admits it has not checked, on the commercial side specifically, without resolving any of it.
What decides whether any of this matters is a question no connector in this repo can reach. Whether a proceduralist would switch from an owned, amortised instrument to a per-case disposable, specifically on the strength of the grade-III recurrence gap now documented, is formally recorded as evidence class 3 — a stakeholder-future claim no source can settle [claim 63: unconfirmed] — and the same is true of whether patients will accept an unsedated office RF procedure at the rate they accept existing modalities [claim 64: unconfirmed]. That sits next to unresolved context from the domain itself: the AGA's own guideline states hemorrhoid diagnosis and treatment "is within the purview of the gastroenterologist," while ASCRS maintains a separate, colorectal-surgery-authored guideline for the same disease, and this dossier does not establish what share of grade II-III patients enter through one specialty rather than the other [dossier: internal-hemorrhoids-office-based-treatment]. Nor does it establish how large the addressable population is in the first place — the one US prevalence figure located is a tertiary-source review-article number, not grade-stratified, and grade-specific prevalence was searched for and not found [dossier: internal-hemorrhoids-office-based-treatment].
Every one of these sixteen claims is a regulatory-database fact about what somebody else was permitted to sell. None is a payment level, a procedure volume, a price, a market share, or a patent. The business case added to the file since the last narrative touches none of this list — it added eight new unverified claims (below), and moved no existing tag.
Reimbursement — every leg failed independently. CPT 46930's descriptor, unit-of-service rule, and the existence of 46945/46946 are unverifiable by design (AMA-licensed) [claim 1: unconfirmed], [claim 2: unconfirmed], [claim 3: unconfirmed]; CCI bundling of 46930 into 46945 is unchecked [claim 4: unconfirmed]; the ~$158 non-facility figure the whole economic claim depends on has never been checked against CMS and rests solely on two commercial aggregator sites [claim 5: unconfirmed]; and the economic claim itself — that a kit must land near $40-60 to the practice — is unchecked end to end [claim 6: unconfirmed]. Two claims are closer to resolved: the 90-day global period [claim 57: unconfirmed] and the non-facility-over-facility RVU split [claim 58: unconfirmed] are sourced to a primary CMS dataset via the research lane, but both stay unconfirmed because a dataset retrieval is not the same as a Verifier pass.
TAM — all three components open, one of them cheaply so. Procedure volume [claim 7: unconfirmed], per-kit price [claim 8: unconfirmed], and addressable share [claim 9: unconfirmed] are all unmeasured; the site-of-service assumption underneath them is too [claim 29: unconfirmed], as is whether commercial payers reimburse comparably to Medicare [claim 30: unconfirmed] — a question this repo's connectors are structurally unable to answer at all.
Eight business-case assumptions, added 2026-09-03, and none of them even attempted yet. Unlike the unconfirmed claims above, which a Verifier checked and could not confirm, these eight carry unverified — the state of a claim nobody has yet run against a connector or a human source. They cover the placement economics the earlier viability deck flagged as missing: a contract-manufacturing quote under the price ceiling [claim 65: unverified]; a console placed at little or no upfront cost, recovered through the disposable margin [claim 66: unverified]; a purchasing practice's own procedure volume clearing a normal capital-equipment payback window [claim 67: unverified]; adoption reaching the file's own 15-25% five-year addressable-share figure [claim 68: unverified]; the lag to first paid consumable order fitting a normal launch runway [claim 69: unverified]; the affordability of building a sales and distribution channel [claim 70: unverified]; a licensing/OEM route for the dosimetry module that would avoid a new full 510(k) [claim 71: unverified]; and the affordability and runnability of a US comparative study proving grade-III superiority over ligation [claim 72: unverified].
FTO and moat — unexamined, not clear. No patent has ever been searched: no patent number is named and the patent connector's API key is unset [claim 11: unconfirmed], [claim 34: unconfirmed]. The only asserted defensible assets — the dosimetry algorithm and applicator geometry — are unconfirmed and depend entirely on the same unexamined search [claim 10: unconfirmed].
The differentiator itself. Whether impedance dosimetry can predict thermal-injury depth closely enough to spare the sphincter complex [claim 31: unconfirmed], whether the applicator can be manufactured inside the cost the economics allow [claim 32: unconfirmed], and whether a single session at grade III beats existing modalities durably [claim 33: unconfirmed] are all unchecked; the underlying mechanism/clinical-risk claim is unconfirmed too [claim 12: unconfirmed].
Whether the field is closing, not opening. No connector confirms the HET Bipolar line is still actively marketed [claim 49: unconfirmed] or that no competitor is extending toward grade III [claim 50: unconfirmed]; whether FDA will accept a grade II-and-III indication on a grade-II predicate history is an open substantial-equivalence question [claim 51: unconfirmed]; and Ultroid's own console-and-disposable-probe business carries a 2016 FDA quality-system recall, terminated, whose applicability could not be confirmed through available connectors [claim 54: unconfirmed]. One caution against reading the clinical gap as a clean run: a modified rubber-band-ligation technique reported 3-month recurrence of 5.4% against 13.6% and eliminated delayed massive bleeding — the incumbent modality may be improving on its own [claim 62: unconfirmed].
Two questions formally recorded as unanswerable by any source. Whether proceduralists would switch to a per-case disposable on the strength of the grade-III recurrence gap [claim 63: unconfirmed] and whether patients accept an unsedated office RF procedure at existing rates [claim 64: unconfirmed] are both evidence class 3 — stakeholder-future claims the file states outright that no connector can settle. The same is true of the narrower switching and practice-pattern assumptions underneath them [claim 15: unconfirmed], [claim 24: unconfirmed], [claim 25: unconfirmed], [claim 26: unconfirmed], [claim 27: unconfirmed], [claim 28: unconfirmed], [claim 48: unconfirmed].
Two corrections, both favorable, and one gap they leave standing. The reading that the panel question had moved toward Part 876 is refuted [claim 19: refuted], as is the premise that no predicate had been identified at all [claim 46: refuted] — five now are, by K-number. A third correction is partial: "no RF-specific office hemorrhoid device was found in openFDA at all" is refuted, but only that half — no product code has been established for this candidate's own device, and that half stands open [claim 23: refuted]. One line, a 25-year hemorrhoid clearance scan, has never been put to a Verifier at all [claim 47: unverified].
Dossier context that has not become a claim. The two societies that could plausibly own this referral pathway do not agree on who sees the patient first — AGA's guideline states diagnosis and treatment of hemorrhoids "is within the purview of the gastroenterologist," while ASCRS maintains its own colorectal-surgery guideline for the same disease, and no source located this pass states what fraction of grade II-III patients enter through primary care, gastroenterology, or colorectal surgery directly [dossier: internal-hemorrhoids-office-based-treatment]. Grade-specific US prevalence — the number that would size this candidate's actual addressable population — was searched for and not found; the one located US prevalence figure ("approximately 10 million individuals") is a tertiary-source review-article number with no stated primary source and is not grade-stratified [dossier: internal-hemorrhoids-office-based-treatment]. The user-groups-and-incentives section of the dossier was not searched at all this pass [dossier: internal-hemorrhoids-office-based-treatment].
All three decks carry source_updated: 2026-09-03, matching the candidate's current updated: stamp, and check_decks.py reports all three current, not stale. That agreement is mechanical rather than substantive: each deck was actually built 2026-08-30, before the business case appended the eight new claims [claim 65: unverified] through [claim 72: unverified] to the file on 2026-09-03, and no deck references any of them — the stamps moved because no claim any deck cites has changed tag, not because a deck was rebuilt against the business case. What follows is the three lenses' view as of 2026-08-30, and it is silent on the eight business-case assumptions.
The desirability deck turns on the proceduralist's willingness to trade an owned, amortised instrument for a per-case disposable. Research-lane findings gave that condition a sharper, numeric edge — a measured 47.5% recurrence at 12 months [claim 59: unconfirmed] and a 90-day global period that puts recurrence on the physician's own P&L [claim 57: unconfirmed] — but the condition itself is still formally unanswerable by any connector: switching is evidence class 3 [claim 63: unconfirmed].
"whether a proceduralist will trade an owned, amortised instrument for a per-case disposable, on a durability promise that is unproven at launch" — the load-bearing condition of the desirability deck (built 2026-08-30).
The viability deck turns on a subtraction the candidate's own title concedes it was designed around: the actual non-facility payment against the actual cost of a dosimetry-bearing disposable. Both halves remain unmeasured — the payment figure has never been checked against a primary CMS source [claim 5: unconfirmed] and no manufacturing quote has ever been sought [claim 32: unconfirmed], a gap the business case has since restated as its own first assumption [claim 65: unverified] — even though two of the billing rules around that subtraction have sourced answers that favor the candidate [claim 57: unconfirmed], [claim 58: unconfirmed].
"the actual non-facility payment for the procedure and the actual cost of a dosimetry-bearing disposable — the two halves of the subtraction the candidate itself says decides it" — the load-bearing condition of the viability deck (built 2026-08-30).
The feasibility deck turns on the same grade-III boundary the regulatory record makes visible: whether this device can be evidenced and cleared at grade III, the half of its own indication for which no bipolar or RF applicator predicate exists.
"whether this device can be evidenced and cleared at grade III — the half of its own indication for which no bipolar or RF applicator predicate exists" — the load-bearing condition of the feasibility deck (built 2026-08-30).
All three lenses converge on the same ground — grade III is simultaneously the only regulatory territory this candidate can plausibly call unoccupied [claim 42: verified], the endpoint the clinical case now has numbers behind [claim 59: unconfirmed], [claim 60: unconfirmed], and the reason a proceduralist would have to be persuaded at all. Where they diverge is in what kind of unresolved each condition is. The feasibility and viability conditions are, in principle, answerable by a lookup, a filing, or a quote — an FDA pre-submission, two CMS cache files, and a contract-manufacturing quote, none of which face any structural obstacle. The desirability condition does not have that exit: it is the one load- bearing question in this file that the candidate's own record states, in terms, no source can ever settle [claim 63: unconfirmed]. The business case's eight new assumptions sit mostly inside the viability lens's territory — placement, payback, channel cost, licensing — and none of them has been checked either, so that lens's open half has gotten longer without any deck yet being rebuilt to say so.
If grade III turns out to be reachable on the frontmatter's own regulatory route, and if the non-facility payment and disposable cost land where the file's own economic claim assumes they must, does a proceduralist facing a measured 47.5% recurrence and a 90-day global period that already puts that recurrence on their own ledger actually trade an owned instrument for a per-case disposable to fix it — or does the field's busiest and most recently entrenched incumbent close that grade-III gap first, on hardware nobody would have to switch to? The business case has since added eight more conditions to that same question — a manufacturing quote, a placement model, a payback window, a channel budget, a licensing alternative, a comparative-study budget — and not one of them has been checked either; the question is now longer, not narrower, than it was at the last build.